Ensign Peak Advisors Inc Invests $1.08 Million in agilon health, inc. (NYSE:AGL)

Ensign Peak Advisors Inc bought a new position in shares of agilon health, inc. (NYSE:AGL – Get Rating) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 45,890 shares of the company’s stock, valued at approximately $1,075,000.

Several other institutional investors and hedge funds have also bought and sold shares of AGL. FMR LLC boosted its stake in agilon health by 14.9% during the second quarter. FMR LLC now owns 34,862,287 shares of the company’s stock worth $761,043,000 after acquiring an additional 4,512,008 shares in the last quarter. Durable Capital Partners LP boosted its stake in agilon health by 34.0% during the third quarter. Durable Capital Partners LP now owns 9,429,055 shares of the company’s stock worth $220,828,000 after acquiring an additional 2,392,134 shares in the last quarter. Wellington Management Group LLP boosted its stake in agilon health by 11.0% during the first quarter. Wellington Management Group LLP now owns 18,578,035 shares of the company’s stock worth $470,953,000 after acquiring an additional 1,834,890 shares in the last quarter. Capital Research Global Investors boosted its stake in agilon health by 18.4% during the first quarter. Capital Research Global Investors now owns 9,867,875 shares of the company’s stock worth $250,151,000 after acquiring an additional 1,536,506 shares in the last quarter. Finally, BlackRock Inc. boosted its stake in agilon health by 20.9% during the third quarter. BlackRock Inc. now owns 8,566,086 shares of the company’s stock worth $200,616,000 after acquiring an additional 1,480,319 shares in the last quarter.

Insider Activity

In other news, insider Benjamin Kornitzer sold 5,398 shares of the stock in a transaction dated Friday, December 16th. The shares were sold at an average price of $16.82, for a total value of $90,794.36. Following the completion of the sale, the insider now owns 10,426 shares in the company, valued at $175,365.32. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, insider Benjamin Shaker sold 20,723 shares of the firm’s stock in a transaction dated Wednesday, January 18th. The shares were sold at an average price of $19.78, for a total transaction of $409,900.94. Following the completion of the sale, the insider now owns 25,625 shares in the company, valued at $506,862.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Benjamin Kornitzer sold 5,398 shares of the firm’s stock in a transaction dated Friday, December 16th. The stock was sold at an average price of $16.82, for a total transaction of $90,794.36. Following the sale, the insider now owns 10,426 shares of the company’s stock, valued at approximately $175,365.32. The disclosure for this sale can be found here. Insiders sold a total of 70,864 shares of company stock worth $1,515,177 over the last quarter. Insiders own 3.30% of the company’s stock.

agilon health Stock Performance

Shares of AGL stock opened at $22.84 on Friday. The firm has a 50-day moving average of $21.10 and a 200-day moving average of $20.31. The company has a market cap of $9.44 billion, a P/E ratio of -87.84 and a beta of 1.09. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.71 and a quick ratio of 2.71. agilon health, inc. has a one year low of $14.82 and a one year high of $28.36.

Analysts Set New Price Targets

Several brokerages recently issued reports on AGL. Wells Fargo & Company cut their target price on shares of agilon health from $28.00 to $22.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 15th. Deutsche Bank Aktiengesellschaft raised their price objective on shares of agilon health from $26.00 to $28.00 in a research note on Friday, March 3rd. The Goldman Sachs Group dropped their price objective on shares of agilon health from $38.00 to $34.00 and set a “buy” rating on the stock in a research note on Tuesday, November 15th. Guggenheim raised their price objective on shares of agilon health from $21.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, March 6th. Finally, Stifel Nicolaus started coverage on shares of agilon health in a research note on Thursday, December 8th. They issued a “buy” rating and a $23.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $28.63.

agilon health Company Profile

(Get Rating)

agilon health, inc. offers healthcare services for seniors through primary care physicians in the communities of the United States. As of December 31, 2021, it served approximately 238,000 senior members, which included 186,300 medicare advantage members and 51,700 medicare fee-for-service beneficiaries.